Lupin To Spin Off Healthcare Division
Indian drugmaker Lupin Ltd. has announced that it spinned off its consumer healthcare business with effect from July 1. The newly formed wholly owned subsidiary will be called as LupinLife Consumer Healthcare Ltd.
Anil Kaushal will lead the new independent entity as the chief executive officer, the company said in an exchange filing on Tuesday. The company expects this move to enhance focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth.
Since its inception in 2017, the company has emerged as a strong over-the-counter healthcare business with a portfolio of scientifically formulated and trusted brands such as Softovac, Beplex Forte, Corcium and Aptivate.
"This carve-out marks an exciting new chapter in our consumer healthcare journey. We are committed to offering world-class OTC products and wellness solutions for Indian consumers. LCH is well-positioned to scale with agility, innovate with intent, and expand access to wellness solutions across India,” said Anil V Kaushal, chief executive officer, LupinLife Consumer Healthcare.
Lupin Q4 Results
Lupin's consolidated net profit more than doubled in the fourth quarter of the financial year to Rs 772 crore, beating analysts' estimates. Revenue for the quarter under review rose 14.2% to Rs 5,667 crore. The rise in revenue was led by surge in sales in North America and other developed markets.
North America sales grew 19% year-on-year, accounting for 41% of global sales in the fourth quarter. The company received seven Abbreviated New Drug Applications or ANDA approvals from the USFDA and launched two products in the quarter in the US. Lupin now has 138 generic products in its largest market.
Shares of Lupin closed 1.18% higher at Rs 1,960.90 per share. This compares with a 0.10% advance in the benchmark Nifty 50. It has risen 21.34% in the last 12 months and fallen 16.76% year-to-date.
Out of 38 analysts tracking the company, 24 maintain a 'buy' rating, 10 recommend a 'hold' and four suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 16%.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.